Sort
82,697 grants matching “vaccine development”
CANCER CHEMOTHERAPY PROGRAM PROJECT
$1,526,040Sloan-Kettering Institute For Cancer Res · P01 · FY2002 · CA
Cellular & Molecular Defects in Human B Cell Development
$1,525,650Charlotte Cunningham-Rundles · Icahn School Of Medicine At Mount Sinai · P01 · FY2010 · AI
Mechanisms of immune-mediated protection and pathogenesis during viral infections
$1,525,332Julie Fox · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Defining Factors Controlling HIV Rebound
$1,525,228Jerome A. Zack · University Of California Los Angeles · P01 · FY2018 · AI
MANUFACTURE OF PLASMID DNA DRUG SUBSTANCE AND DRUG PRODUCT
$1,524,929Rachel Ginther · Midwest Research Institute · N02 · FY2024 · CA
IL-2:IL-15 cytokine receptor: implications for cancer therapy and vaccine
$1,524,881Thomas Waldmann · Division Of Clinical Sciences - Nci · ZIA · FY2017 · CA
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components
$1,524,758Sandra D. Comer · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · UG3 · FY2019 · DA
DIGITAL HEALTH SOLUTIONS FOR COVID-19: CLEAR2GO
$1,524,610Adarbad Master · Icrypto, Inc. · N01 · FY2021 · CA
HPV, cervical neoplasia, and vaccination
$1,524,463Allan Hildesheim · Division Of Cancer Epidemiology And Genetics · ZIA · FY2010 · CA
Mapping Immune Responses to CMV in Renal Transplant Recipients
$1,524,094Elaine F Reed · University Of California Los Angeles · U19 · FY2021 · AI
Enhancing evidence generation by linking randomized clinical trials (RCTs) to real world data (RWD)
$1,523,906Mehdi Najafzadeh · Brigham And Women'S Hospital · U01 · FY2020 · FD
Task 19: GMP Manufacturing for a Malaria Vaccine Phase I Trial
$1,523,776James Richardson · Advanced Bioscience Laboratories, Inc. · N01 · FY2016 · AI
Cancer Immunotherapy Trials Network Central Operations and Statistical Center
$1,523,677Martin Cheever · Fred Hutchinson Cancer Research Center · U01 · FY2010 · CA
Units for HIV/AIDS Clinical Trials Networks
$1,523,588Ram Yogev · Lurie Children'S Hospital Of Chicago · UM1 · FY2012 · AI
Dengue Epitope Vaccine,Tetravalent &MHCII-Targeted
$1,523,567Johns Hopkins University · U19 · FY2004 · AI
Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies
$1,522,830Alon Herschhorn · University Of Minnesota · U01 · FY2024 · AI
Characterization of Biological Nanoparticle Subsets
$1,522,674Jennifer Jones · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
1/2 CCNY-MSKCC Partnership for Cancer Research, Education and Community Outreach
$1,522,608Karen Hubbard · City College Of New York · U54 · FY2022 · CA
1/2 CCNY-MSKCC Partnership for Cancer Research, Education and Community Outreach
$1,522,608Karen Hubbard · City College Of New York · U54 · FY2023 · CA
Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine Abuse
$1,522,479Chang-Guo Zhan · University Of Kentucky · UH3 · FY2017 · DA
Human monoclonal antibodies targeting infectious pathogens
$1,521,970Joshua Hoong Yu Tan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Immune Regulation in Mycobacterial and Fungal Infections
$1,521,960Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Virus Ecology Unit - COVID-19 response
$1,521,676Vincent Munster · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
$1,521,291Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Strategies for Cancer Immunotherapy Clinical Trials
$1,521,291Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA